EGFR and lung cancer: Can an end-to-end deep learning network model be used to identify patients with stage IV epidermal growth factor receptor (EGFR) variant–positive non–small cell lung cancer who will not benefit from EGFR–tyrosine kinase inhibitor (TKI) therapy?